Cybin Inc Com (CX) - 5i Research

Cybin Inc Com (CX $0.14)
- View CX Profile
- View Questions on CX

{tplLang.businessdescription | toLang tLang}

{ profileData.description }

{tplLang.details | toLang tLang}

{tplLang.ceo | toLang tLang}

{profileData.profile.details.ceo}

{tplLang.employees | toLang tLang}

{profileData.profile.details.employees | numeraljs '0,0'}

{tplLang.issuetype | toLang tLang}

{profileData.profile.details.issuetype | asIssueType}

{tplLang.industryclassifications | toLang tLang}

{tplLang.sector | toLang tLang}

{profileData.profile.classification.sector}

{tplLang.industry | toLang tLang}

{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.

AbbVie Inc. (ABBV $208.36)
- $208.36 P/E (TTM): 90.0X Cap: $366.64B
- View ABBV Profile
- View Questions on ABBV
Cybin Inc Com (CX $0.14)
- View CX Profile
- View Questions on CX
COMPASS Pathways Plc (CMPS $4.76)
- $4.76 Cap: $439M
- View CMPS Profile
- View Questions on CMPS
Mind Medicine (MindMed) Inc. (MNMD $9.99)
- $9.99 Cap: $744M
- View MNMD Profile
- View Questions on MNMD

Q: What is your opinion of ABBV buying an experimental drug derived in the psychedelic space from private company Gilgamesh for 1.2B?. Do you think with some of these psychedelic companies now getting phase 2 and phase 3 trials wrapped up on their potential drug offerings that the psychedelic market might get some legs in the near future as the big pharma companies look for the next big thing. ? With these being very spec who would be you picks in the space for fun money?

Read Answer Asked by Kolbi on August 26, 2025